| Literature DB >> 33176933 |
José Gonçalves1, Tom Koritnik2, Verica Mioč2, Marija Trkov2, Maja Bolješič2, Nataša Berginc2, Katarina Prosenc2, Tadeja Kotar3, Metka Paragi2.
Abstract
Previous studies on SARS-CoV and MERS-CoV reported the detection of viral RNA in the stool of both symptomatic and asymptomatic individuals. These clinical observations suggest that municipal and hospital wastewater from affected communities may contain SARS-CoV-2 RNA. Recent studies have also reported the presence of SARS-CoV-2 RNA in human feces. Wastewater-based epidemiology (WBE) is a promising approach to understand the prevalence of viruses in a given catchment population, as wastewater contains viruses from symptomatic and asymptomatic individuals. The current study reports the first detection of SARS-CoV-2 RNA in untreated wastewater in Slovenia. Two sizes of centrifugal filters were tested: 30 kDa and 10 kDA AMICON® Ultra-15 Centrifugal Filters, where 10 kDA resulted in a higher concentration factor and higher recovery efficiency. The results in hospital wastewater show that WBE can be used for monitoring COVID -19 and could be applied in municipal wastewater treatment plants as a potential complementary tool for public health monitoring at population level.Entities:
Keywords: COVID-19; SARS-CoV-2; Virology; Wastewater; Wastewater-based epidemiology; qPCR
Year: 2020 PMID: 33176933 PMCID: PMC7591869 DOI: 10.1016/j.scitotenv.2020.143226
Source DB: PubMed Journal: Sci Total Environ ISSN: 0048-9697 Impact factor: 7.963
Primers and probes used to detect SARS-CoV-2 RNA and their sequences.
| Target | Primer or Probe | Sequence (5′-3′) | Reference |
|---|---|---|---|
| RdRP | RdRP_SARSr-F | GTGARATGGTCATGTGTGGCGG | |
| RdRP_SARSr-P2 | FAM-CAGGTGGAACCTCATCAGGAGATGC-BBQ | ||
| RdRP_SARSr-P1 | FAM-CCAGGTGGWACRTCATCMGGTGATGC-BBQ | ||
| RdRP_SARSr-R | CARATGTTAAASACACTATTAGCATA | ||
| E | E_Sarbeco_F | ACAGGTACGTTAATAGTTAATAGCGT | |
| E_Sarbeco_P1 | FAM-ACACTAGCCATCCTTACTGCGCTTCG-BBQ | ||
| E_Sarbeco_R | ATATTGCAGCAGTACGCACACA |
Fig. 1Correlation between Cq values and Log10 dilutions of SARS-CoV-2 RNA positive sample for A) RdRP gene assay and B) E gene assay. The equation and correlation coefficient (R2) for the standard curve are given. Plotted Cq values are average values from triplicate measurements and error bars show the standard deviation from the average and may be hidden by the symbols.
Screening of 30 kDa and 10kDA AMICON® Ultra-15 Centrifugal Filters to concentrate SARS-CoV-2 from wastewaters, using two RT-qPCR assay targets.
| 30 kDa AMICON® Ultra-15 | 10 kDa AMICON® Ultra-15 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Run | SARS-CoV-2 recovery for RdRP (Cq) | SARS-CoV-2 recovery for RdRP (Cq) | ||||||||
| Non concentrate | Eluate | Flow-through | Concentration Factor (fold) | Recovery Efficiency (%) | Non concentrate | Eluate | Flow-through | Concentration | Recovery | |
| 1 | 26.82 | 19.30 | 41.17 | 240.6 | 48.1 | 28.60 | 21.89 | nd | 136.4 | 27.3 |
| 2 | 26.94 | 19.65 | nd | 203.6 | 40.7 | 28.73 | 20.30 | nd | 428.7 | 96.5 |
| 3 | 27.08 | 19.14 | nd | 326.6 | 65.3 | 27.77 | 21.36 | nd | 110.0 | 22.0 |
| Run | SARS-CoV-2 recovery for E gene (Cq) | SARS-CoV-2 recovery for E gene (Cq) | ||||||||
| Non | Eluate | Flow-through | Concentration Factor (fold) | Recovery Efficiency (%) | Non concentrate | Eluate | Flow-through | Concentration | Recovery | |
| 1 | 24.45 | 17.78 | 37.24 | 129.3 | 25.9 | 26.27 | 19.33 | nd | 154.2 | 30.8 |
| 2 | 25.36 | 18.02 | nd | 210.8 | 42.2 | 26.31 | 18.11 | nd | 389.3 | 77.9 |
| 3 | 25.16 | 17.63 | nd | 241.9 | 48.4 | 26.42 | 19.14 | nd | 199.2 | 39.8 |
nd – non detectable.
Average RT-qPCR Cq values for the RdRP and E gene assays from the collected samples and the detection rate during the sample period, for concentration with 30 kDa and 10 kDa AMICON® Ultra-15 centrifugal filters.
| SARS-CoV-2 assay for RdRP (Average Cq value) | SARS-CoV-2 assay for E (Average Cq value) | ||||||
|---|---|---|---|---|---|---|---|
| Date | BC | E | FT | BC | E | FT | |
| 30 kDa AMICON® Ultra-15 | 1.6.2020 | nd | nd | nd | nd | nd | nd |
| 2.6.2020 | nd | nd | nd | nd | nd | nd | |
| 3.6.2020 | nd | nd | nd | nd | nd | nd | |
| 4.6.2020 | nd | nd | nd | nd | nd | nd | |
| 5.6.2020 | nd | nd | nd | nd | nd | nd | |
| 6.6.2020 | nd | nd | nd | nd | nd | nd | |
| 7.6.2020 | nd | nd | nd | nd | nd | nd | |
| 8.6.2020 | nd | nd | nd | nd | nd | nd | |
| 9.6.2020 | nd | nd | nd | nd | nd | nd | |
| 10.6.2020 | nd | 38.46 | nd | nd | 38.45 | nd | |
| 11.6.2020 | nd | nd | nd | nd | nd | nd | |
| 12.6.2020 | 36.22 | nd | nd | 37.43 | 38.42 | nd | |
| 13.6.2020 | 37.03 | nd | nd | 36.61 | nd | nd | |
| 14.6.2020 | nd | 35.4 | nd | nd | 35.4 | nd | |
| 15.6.2020 | nd | nd | nd | nd | 38.12 | nd | |
| 10 kDa AMICON® Ultra-15 | 1.6.2020 | nd | nd | nd | nd | nd | nd |
| 2.6.2020 | nd | nd | nd | nd | nd | nd | |
| 3.6.2020 | nd | nd | nd | nd | nd | nd | |
| 4.6.2020 | nd | nd | nd | nd | nd | nd | |
| 5.6.2020 | nd | 36.4 | nd | nd | nd | nd | |
| 6.6.2020 | nd | nd | nd | nd | nd | nd | |
| 7.6.2020 | nd | 36.81 | nd | nd | nd | nd | |
| 8.6.2020 | nd | 33.91 | nd | nd | nd | nd | |
| 9.6.2020 | nd | 29.65 | nd | nd | 38.12 | nd | |
| 10.6.2020 | nd | 29.75 | nd | nd | 34.98 | nd | |
| 11.6.2020 | nd | 34.36 | nd | nd | 34.61 | nd | |
| 12.6.2020 | 36.22 | 33.03 | nd | 37.43 | 33.61 | nd | |
| 13.6.2020 | 37.03 | 36.23 | nd | 36.61 | 37.89 | nd | |
| 14.6.2020 | nd | 34.96 | nd | nd | 35.52 | nd | |
| 15.6.2020 | nd | 35.24 | nd | nd | nd | nd | |
nd – non-detectable.
Fig. 2Number of hospitalized patients diagnosed with COVID-19 and the hypothetical number of copies for RdRP and E gene assays.